Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01018992 · ClinicalTrials.gov registry record · Phase 2
Evaluation of GSK561679 in Women With Post-Traumatic Stress Disorder
A Phase 2 study, sponsored by Emory University.
- Completed
- Registry status
- Phase 2
- Development phase
- 267
- Enrollment target
NCT01018992: Completed Phase 2 study, sponsored by Emory University.
NCT01018992 is a Phase 2 study that has completed, run by Emory University. The registered enrollment target is 267 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (101% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01018992, a Phase 2 study, has completed, sponsored by Emory University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 267 participants
- Enrollment target
Study Summary
This study will test the hypothesis of whether an antagonist at the corticotropin releasing factor type 1 (CRF1) receptor (i.e. GSK561679) is superior to placebo in reducing symptoms of post-traumatic stress disorder (PTSD).
Primary Outcome
The CAPS is a semi-structured clinical interview providing a measure of the severity of PTSD symptoms. A severity score is calculated by summing the frequency and intensity scores for each of the 17 DSM-IV criteria symptoms. The severity of symptoms is rated on a scale from 0-4, where, 0 = Absent, 1 = Mild/subthreshold; 2 = Moderate/ threshold, 3 = Severe/markedly elevated and 4 = Extreme/ incapacitating. Scores may range from 0 (no symptoms) to 136 (severe symptoms). Change is the difference in
Interventions
- DRUG Placebo
- DRUG GSK561679
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 267 participants |
| Start Date | 2009-12 |
| Est. Completion | 2014-08 |
| Phase | Phase 2 |
What the finished NCT01018992 record still lists
NCT01018992 is an interventional study that assigns participants to a tested intervention. The registered 267 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (101% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01018992 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01018992 about?
NCT01018992 is a clinical study titled "Evaluation of GSK561679 in Women With Post-Traumatic Stress Disorder". This study will test the hypothesis of whether an antagonist at the corticotropin releasing factor type 1 (CRF1) receptor (i.e. GSK561679) is superior to placebo in reducing symptoms of post-traumatic stress disorder (PTSD).
What is the current status of trial NCT01018992?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 267 participants. The study started on 2009-12. Estimated completion is 2014-08.
What interventions are being tested in trial NCT01018992?
The interventions under investigation include: Placebo (DRUG), GSK561679 (DRUG).
Who is sponsoring clinical trial NCT01018992?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01018992's enrollment target sits among peer trials
267 209th of 2000 higher than 1,792 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04997109 · 267 participants · NA
Telemedicine in Early Childhood Constraint Therapy in Cerebral Palsy
- NCT05355701 · 267 participants · Phase 1
A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations.
- NCT06203509 · 267 participants · NA
Improving Care Transitions for Medicaid Insured Individuals With Co-occurring Serious Mental Illness
- NCT05000632 · 268 participants · NA
Smoke Free SafeCare: Establishing a Smoke Free Home in CPS-involved Families
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia